An Open-label, Non-randomised, Phase I Study to Assess the Effect of Single and Multiple Oral Doses of Osimertinib (TAGRISSO) on the Pharmacokinetics of a P-glycoprotein Probe Drug (Fexofenadine) in Patients With Advanced EGFRm NSCLC That Have Progressed on a Prior EGFR-TKI Regimen
Latest Information Update: 15 Nov 2022
At a glance
- Drugs Osimertinib (Primary) ; Fexofenadine
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 10 Nov 2022 Status changed from active, no longer recruiting to completed.
- 23 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.
- 17 May 2021 Planned End Date changed from 5 Mar 2021 to 31 Dec 2021.